Showing 7441-7450 of 8649 results for "".
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- Hoya Vision Care and Haag-Streit Partner to Combat Myopiahttps://modernod.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/Hoya Vision Care announced a strategic partnership with Haag-Streit to help address the global rise of myopia in children. The global sales and marketing agreement creates a preferred partnership between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar M
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Gyroscope Therapeutics Presents Positive Interim Phase 1/2 Data for Investigational Gene Therapyhttps://modernod.com/news/gyroscope-therapeutics-announces-presentation-of-positive-interim-phase-12-data-for-investigational-gene-therapy-gt005-at-retina-society-annual-scientific-meeting/2480312/Gyroscope Therapeutics announced positive interim data from the
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op
- Nicox Does Not Meet Primary or Secondary Endpoints in Phase 2b Mississippi Blepharitis Trialhttps://modernod.com/news/nicox-does-not-meet-primary-or-secondary-endpoint-in-phase-2b-mississippi-blepharitis-trial/2480300/Nicox SA announced the results from its Mississippi phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations o
- Digital Vision and Neurolens Collaborate to Increase Prism Specificityhttps://modernod.com/news/digital-vision-and-neurolens-collaborate-to-increase-prism-specificity/2480297/With the aim of providing a new standard of care when addressing the growing prevalence of eye misalignment, Neurolens and Digital
- FYidoctors Makes Expansion into US Markethttps://modernod.com/news/fyidoctors-makes-expansion-into-us-market/2480296/Canadian eye care provider FYidoctors announced that it has expanded its geographic operations into the US marketplace with the addition of six leading eye care clinics throughout the state of California. The foray marks a major company milestone as the first time FYidoctors has ad
- TissueTech Hosts Inaugural Leadership Summit to Discuss Best Practices on Regenerative Medicinehttps://modernod.com/news/tissuetech-hosts-inaugural-leadership-summit-to-discuss-best-practices-on-regenerative-medicine/2480288/TissueTech announced that the company had completed its first physician leadership summit, Beyond the Horizon 2021,